Form 4: Soleno Therapeutics Merger Completes, RSUs Converted

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., resulting in the conversion of restricted stock units into cash.

Summary

• The filing reports on changes in beneficial ownership for Mark W. Hahn, a Director at Soleno Therapeutics Inc.
• The earliest transaction date reported is May 18, 2026.
• On May 18, 2026, 10,046 shares of Common Stock were acquired, represented by previously reported restricted stock units (RSUs).
• These RSUs were cancelled and converted into the right to receive $53.00 in cash per RSU as part of a merger agreement.
• The merger involved Soleno Therapeutics, Inc., Neocrine Biosciences, Inc. (Parent), and Sigma Merger Sub, Inc. (Merger Sub).
• Soleno Therapeutics, Inc. continues as the surviving corporation and a wholly owned subsidiary of Parent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on a completed transaction and the conversion of equity awards rather than new operational or financial performance.

Positives

• Completion of a merger transaction, indicating a strategic move for the company.
• Shareholders holding RSUs received a cash payout of $53.00 per unit, providing immediate value realization.

Negatives

• The cancellation of RSUs means that equity holders no longer hold direct ownership in the surviving entity, potentially limiting future upside participation.

Risks

• The filing does not explicitly detail risks associated with the merger itself, but typical risks include integration challenges, potential regulatory hurdles, and market reception of the new entity.

Future Outlook

The future outlook for the combined entity, Neocrine Biosciences, Inc., is not detailed in this Form 4 filing, which primarily reports on the completion of the merger and the conversion of equity awards.

Management Comments

• The filing notes that each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash.

Industry Context

StockSavvy.ai notes that this Form 4 filing signifies the completion of a significant corporate event, a merger, for Soleno Therapeutics, Inc. Such transactions are common in the biotechnology and pharmaceutical sectors as companies seek to consolidate, gain access to new technologies, or achieve economies of scale. The conversion of RSUs into cash is a standard outcome in acquisition scenarios.

Stakeholder Impact

• Shareholders who held RSUs will receive a cash payout, realizing immediate value from their holdings.
• Other shareholders of Soleno Therapeutics, Inc. would have received the merger consideration as per the terms of the merger agreement, which is not detailed in this specific filing.
• Employees who held RSUs will no longer have equity in the company but will receive cash compensation.

Next Steps

• The company will continue operations as a wholly owned subsidiary of Neocrine Biosciences, Inc.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Neocrine Biosciences, Restricted Stock Units, RSU, SEC Form 4, Beneficial Ownership, Mark W. Hahn, Director